Subcutaneous Ocrelizumab Funded for Multiple Sclerosis
Pharmac have, today, announced they will fund subcutaneous ocrelizumab for multiple sclerosis. Multiple Sclerosis NZ and the wider MS community warmly welcome this landmark decision, bringing renewed hope to the lives of those affected by MS. We hope this decision is the first of many in improving patient experiences, access to treatments and system improvements. […]